Prognostic and Predictive Factors in Early-Stage Breast Cancer

Author:

Cianfrocca Mary1,Goldstein Lori J.1

Affiliation:

1. Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

Abstract

Abstract Learning Objectives After completing this course, the reader will be able to: Differentiate between prognostic and predictive factors in early-stage breast cancer. Identify prognostic factors used to determine the risk of recurrence and death for a patient with early-stage breast cancer. Identify predictive factors used to determine the optimal therapy for a patient with early-stage breast cancer. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com Breast cancer is the most common malignancy among American women. Due to increased screening, the majority of patients present with early-stage breast cancer. The Oxford Overview Analysis demonstrates that adjuvant hormonal therapy and polychemotherapy reduce the risk of recurrence and death from breast cancer. Adjuvant systemic therapy, however, has associated risks and it would be useful to be able to optimally select patients most likely to benefit. The purpose of adjuvant systemic therapy is to eradicate distant micrometastatic deposits. It is essential therefore to be able to estimate an individual patient's risk of harboring clinically silent micrometastatic disease using established prognostic factors. It is also beneficial to be able to select the optimal adjuvant therapy for an individual patient based on established predictive factors. It is standard practice to administer systemic therapy to all patients with lymph node-positive disease. However, there are clearly differences among node-positive women that may warrant a more aggressive therapeutic approach. Furthermore, there are many node-negative women who would also benefit from adjuvant systemic therapy. Prognostic factors therefore must be differentiated from predictive factors. A prognostic factor is any measurement available at the time of surgery that correlates with disease-free or overall survival in the absence of systemic adjuvant therapy and, as a result, is able to correlate with the natural history of the disease. In contrast, a predictive factor is any measurement associated with response to a given therapy. Some factors, such as hormone receptors and HER2/neu overexpression, are both prognostic and predictive.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Reference91 articles.

1. Cancer statistics, 2001;Landis;CA Cancer J Clin,2001

2. Global breast cancer mortality statistics;Mettlin;CA Cancer J Clin,1999

3. The National Cancer Data Base 10-year survey of breast cancer treatment at hospitals in the United States;Bland;Cancer,1998

4. Early Breast Cancer Trialists' Collaborative Group;Tamoxifen for early breast cancer: an overview of the randomised trials;Lancet,1998

5. Early Breast Cancer Trialists' Collaborative Group;Polychemotherapy for early breast cancer: an overview of the randomised trials;Lancet,1998

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3